Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Green-Lights Medrobotics' Flex Robotic System For Transoral Head And Neck Surgery

Executive Summary

Medrobotics Corp. recently received US FDA 510(k) clearance for its Flex Robotic System for transoral head and neck surgery, a market estimated at roughly $1 billion in the US alone. Although Medrobotics is only the second company to bring a robotic soft-tissue surgical system to market in the US, other novel systems are in development, including a unique robotic system for needlescopic procedures.

You may also be interested in...



Intuitive Still Dominates, But New Robotic Surgery Players Could Speed Penetration

Intuitive Surgical's latest earnings and procedure numbers beat analysts' expectations and further solidified its leading position in surgical robotics. But potential robotic rivals are in the wings with alternative solutions that could make robotic surgery more affordable and accessible, including Cambridge Medical Robotics, Transenterix, Titan Medical, SOFAR and J&J/Google.

Life After NASH For CymaBay: An Interview With CEO Sujal Shah

With up to $100m from Abingworth and a recent $75m FOPO, CymaBay has runway to await pivotal data in primary biliary cholangitis in 2023 for seladelpar, after the candidate failed in NASH. It sees a significant market opportunity in the second-line setting cornered by Intercept.

FDA, Industry To Miss MDUFA V Congressional Deadline; Insiders At Odds Over Future Of Deal

The US agency and the medtech industry still have significant disagreements, which means they will miss a 15 January deadline to send the MDUFA V user-fee deal to Congress. Insiders disagree, however, on how severe those disagreements are and when a deal can be reached.

Topics

Related Companies

UsernamePublicRestriction

Register

MT035946

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel